Cirrhosis, LiverNCT05059795
Volume Resuscitation in Cirrhosis With Sepsis Induced Hypotension
An observational study of Cirrhosis, Liver and Sepsis, run by Post Graduate Institute of Medical Education and Research, Chandigarh at 2 sites in India.
Trial summary
In critically ill patients with liver disease like cirrhosis or ACLF, fluid therapy needs to be instituted after identification of patients who will be fluid responsive and initiate appropriate inotropes early to prevent the mortality associated with fluid overload. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Cirrhosis, Liver, Sepsis, Acute on Chronic Liver Failure
- What is being tested?
- Albumin + electrolyte solution and POCUS guided fluid resuscitation
- How many people
- 350 participants
- Where
- 2 sitesIndia
- Study dates
- 1 Feb 2020to 10 Aug 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients 18-65 years age with cirrhosis of any etiology now presenting with sepsis induced hypotension
Who may be able to join
- Clinical/Imaging or Biopsy proven liver cirrhosis of any etiology
- Hypotension (MAP <65mmHg or SBP <90mmHg)
- 18-65 yrs of age
Who cannot join
- Already received colloid or 2 litres of fluid within the first 2 hours of presentation, without echocardiographic assessment.
- Already on vasopressors/inotropes
- Severe pre-existing cardiopulmonary disease
- Acute Respiratory Distress Syndrome (ARDS)
- Active bleeding like variceal bleed 28
- Cerebrovascular events
Show all 12Show fewer
- Chronic renal disease - End Stage Renal Disease (ESRD)/ patient on renal replacement therapy
- Admission to ICU following liver transplantation, burns, cardiac surgery
- Brain death or likely brain death within 24 hours
- Previous adverse reaction to human albumin solution
- Pregnant or lactating women
- Informed consent refused by patient or attendants
Trial locations and contacts
2 sites in 1 country.
India2 sites
PGIMER
Chandigarh, Chandigarh, 160012
Postgraduate Institute of Medical Education and Research
Chandigarh, 160012
About this study
Official title: To Compare the Effectiveness of Various Methods of Estimating Volume Resuscitation in Patients With Cirrhosis With Sepsis Induced Hypotension
In critically ill patients with liver disease like cirrhosis or ACLF, fluid therapy needs to be instituted after identification of patients who will be fluid responsive and initiate appropriate inotropes early to prevent the mortality associated with fluid overload.
The parameters and methodology used for assessing fluid responsiveness have been studied earlier, but the optimum method is not established. Existing recommendations based on data regarding fluid responsiveness and choice of fluid for resuscitation from intensive care units in general cannot be applied to those with liver disease as the hemodynamic alterations that occur with liver disease, presence of hypoalbuminemia at baseline and presence of cardiac dysfunction interfere with the conventional methods of fluid status assessment, fluid responsiveness as well as the response to different types of resuscitation fluids.
Therefore the investigators attempt to compare various methods to estimate current intravascular volume status of patient which could be helpful in guiding fluid therapy.
Read the detailed description
Objectives:
- To compare the accuracy of central venous pressure and inferior vena cava dynamic assessment and lactate clearance for estimating adequacy of fluid resuscitation in patients with cirrhosis with sepsis induced hypotension .[Time Frame at enrolment, 6 hours, 24 hours]
- Predictors of all-cause mortality at Day 7 and day 28. [Time Frame Day 7 and Day 28]
PATIENTS AND METHODS Study Design: A Prospective observational study
Case Definition:
Cirrhosis will be defined by - "clinical features consistent with chronic liver disease (CLD) including a consistent history as well as a documented complication of CLD (i.e., ascites, varices, hepatic encephalopathy) and/or imaging results consistent with cirrhosis and/or liver histologic findings consistent with cirrhosis" ACLF will be defined as per EASL criteria with documentation of organ failures.
Systemic Inflammatory Response Syndrome (SIRS) - 2 more of following 4
- Oral temperature >38.3oC or <36oC
- Heart Rate > 90 beats/min
- Respiratory Rate >20 breaths/min or PaCO2 <32mmHg
- WBC count >12000/cumm, <4000/cumm or >10% immature band forms Sepsis is a SIRS in response to proven or suspected microbial event 'Sepsis induced hypotension' implies mean arterial pressure < 65 mmHg or a reduction of >40 mm Hg from baseline in the absence of other causes of hypotension Severe sepsis - sepsis-induced tissue hypoperfusion or organ dysfunction (any of the following thought to be due to the infection)
- Sepsis-induced hypotension
- Lactate above upper limits laboratory normal
- Urine output < 0.5 mL/kg/hr for more than 2 hrs despite adequate fluid resuscitation
- Acute lung injury with PaO2/FIO2 < 250 in the absence of pneumonia as infection source
- Acute lung injury with PaO2/FIO2 < 200 in the presence of pneumonia as infection source
- Creatinine > 2.0 mg/dL (176.8 μmol/L)
- Bilirubin > 2 mg/dL (34.2 μmol/L)
- Platelet count < 100,000 μL
- Coagulopathy (international normalized ratio > 1.5) Septic shock is "sepsis induced hypotension despite adequate fluid resuscitation along with organ dysfunction or perfusion abnormality".
Acute kidney injury (AKI) is defined as any of the following:
- Increase in SCr by ≥0.3 mg/dl (≥26.5 μmol/l) within 48 hours; or
- Increase in SCr to ≥1.5 times baseline, which is known or presumed to have occurred within the prior 7 days; or
- Urine volume <0.5 ml/kg/h for 6 hours
Definition of Adequate Intravascular volume - IVC diameter ≥ 18mm and IVCCI <40% Definition of Adequate fluid resuscitation - Achieving MAP ≥ 65mmHg with Fluid bolus
All patients eligible for the study will undergo screening as per the above criteria. The ones who satisfy the criteria will be counselled for participation in the study and written informed consent will be taken from the patient / the legal guardian in patients who are unable to do so. Patient information sheets will also be signed, briefing the patients about why the research work is necessary and also about the methodology.
Detail history and clinical examination will be done in all cases and the findings along with all investigation results will be recorded in a standard case record form. Information would be collected regarding the onset and duration of symptoms, etiology, and severity of disease, other baseline clinical features, demographic characteristics, routine biochemical and hematological investigations.
- After enrolment, baseline samples would be taken for routine investigations and samples for evaluation of sepsis - blood culture, urine culture, fluid cultures, procalcitonin will be taken.
- The patient would be assessed for 5 parameters and will be reassessed 30min and 4hours after starting fluid resuscitation.
- IVC diameter and collapsibility Index
- Serum lactate levels
- Venous-arterial pCO2 difference
- CVP where central line inserted as per treating physician's decision
- ScVO2 where central line available
- The patients in septic shock where IVC diameter <18mm or IVCCI≥40% in spontaneously breathing patients, would be regarded in fluid depleted state and will be given aggressive fluid resuscitation with 20% albumin 100 ml started within 30 min which is a standard fluid of choice in patients with cirrhosis and other fluids - Normal Saline/ balanced salt solution 30ml/kg over 3hrs. (The patients who not fulfil above criteria would be assumed in a fluid replete state and be started on maintenance fluid management along with inotrope support as per standard dosage guidelines) Norepinephrine would be 1st choice vasopressor - started at a dose of 4μg/min and titrated every 20 min to a maximum of 21.3μg/min. If MAP still <65mmHg, Vasopressor would be added starting from a 0.01U/min to 0.04U/min. Adrenaline would be added in shock refractory to both vasopressors in dose of 4-24μg/min.
- Along with fluid and inotrope support, the patient will also receive standard of care including empiric broad spectrum antibiotics, oxygen support/ventilator support if needed.
- MAP would be rechecked 30 min after starting fluid therapy. IVC diameter and IVCCI would also be checked at same time to see if change in MAP (if any) is reflected in the IVC status. Adequate fluid resuscitation would be defined by achieving a MAP ≥ 65mmHg. In patients achieving MAP≥65mmHg, fluid therapy will be continued. The patients still having MAP<65 mmHg will be started on inotrope support according to standard guidelines.
- IVC, IVCCI, Lactate, venous-arterial pCO2 difference, CVP and ScVO2 would be remeasured at 4 hrs.
- The patient would be the followed with serial examinations, calculations of SOFA score, CTP and MELD.
- Samples to test for sepsis such as procalcitonin, galactomannan, beta D Glucan and high sensitivity CRP will be done every 48-72 hours as determined by the treating clinician.
- Cultures for bacterial and fungal sepsis will be taken as per the Liver ICU protocol.
- If discharged earlier, for the purpose of 28-day mortality the patients' kin would be contacted telephonically.
- Data regarding total amount of fluids, type of fluids, urine output, dose and duration of inotropes, initiation of RRT, total days in ICU/Hospital, immediate cause of death (In case of mortality) would be noted.
Presence of Cirrhotic Cardiomyopathy as per updated 2020 CCMC criteria.
CCM is defined as systolic or diastolic dysfunction in the absence of alternative cardiac pathology in concordance with the Cirrhotic Cardiomyopathy Consortium (CCMC) criteria. 9 Systolic dysfunction was defined as an ejection fraction (EF) ≤50% or an absolute value of GLS <18%. LVDD will be defined as presence of 3 of the following 4 criteria: septal early diastolic mitral annular flow velocity (e') <7 cm/s, early diastolic transmitral flow to early diastolic mitral annular velocity (E/e') ≥15, left atrial volume index (LAVI) >34 mL/m2, tricuspid jet maximum velocity >2.8 m/s, in the absence of pulmonary hypertension and the presence of measurable early to late diastolic transmitral flow velocity (E/A) ratio (E/A >2 = grade 3 \& E/A 0.8-2 = grade 2 LVDD). Persons meeting only 2 criteria will be termed as indeterminate for LVDD grade. 19
- Conditions
- Cirrhosis, Liver, Sepsis, Acute on Chronic Liver Failure
- Being tested
- Albumin + electrolyte solution, POCUS guided fluid resuscitation
- Keywords
- Resuscitation in cirrhosis, Inferior vena cava dynamics, Central Venous Pressure in cirrhosis, Lactate clearance in cirrhosis, Acute-on-chronic liver failure, Sepsis in Cirrhosis, Shock in ACLF and Cirrhosis
- Medical subject headings
- Liver Cirrhosis, Sepsis, Acute-On-Chronic Liver Failure, Fibrosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Albumin + electrolyte solutionDrug
Also called Crystalloid
Type of resuscitation fluid, dose and use of inotrope
POCUS guided fluid resuscitationDiagnostic test
Conventional goal directed therapy
| Study group | Role | What they receive |
|---|---|---|
| Cirrhosis/ACLF of any etiology | Not described Receives: Drug: Albumin + electrolyte solution; Diagnostic Test: POCUS guided fluid resuscitation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Achievement of Mean Arterial pressure >65 mmHg
Measured: At the end of 4 hours since admission (time zero)
Secondary outcomes (29)
Requirement of vasopressors
Measured: At the end of 4 hours of admission
Requirement of vasopressors
Measured: At the end of 24 hours of admission
Volume of fluid infused
Dose of albumin
Measured: At the end of 4 hours of admission
Volume of fluid infused
Dose of crystalloid
Measured: At the end of 24 hours of admission
Volume of fluid infused
Total volume of fluids
Measured: At the end of 36 hours of admission
Volume of fluid infused
Dose of albumin and crystalloid
Measured: At the end of 48 hours of admission
Volume of fluid infused
Dose of albumin and crystalloid
Measured: At the end of 72 hours of admission
Incidence of Acute Kidney Injury
Measured: At admission
Incidence of Acute Kidney Injury
Any new episode of AKI documented in the first week of admission
Measured: Day 7
Incidence of new organ dysfunction (encephalopathy, coagulation failure, respiratory failure)
Any new episode of new organ dysfunction documented in the first week of admission
Measured: Day 7
Duration of ICU stay
The total duration of stay in intensive care, which will be assessed till 28 days
Measured: Total duration of ICU stay in days
Duration of hospital stay
The total duration of stay in hospital, which will be assessed till 28 days
Measured: Total duration of admission as a hospital inpatient, assessed till 28 days
Mortality
Incidence of death at the end of 1 week i.e. early mortality
Measured: Day 7
Mortality
Incidence of death at the end of 4 weeks i.e. late mortality
Measured: Day 28
Documentation of Cardiac index
POC ultrasound and echocardiography documentation (Cardiac index), Systemic Vascular resistance index (SVRI) 0h,6h on day 1
Measured: Time zero at admission
Documentation of Cardiac index at 6h
POC ultrasound and echocardiography documentation (Cardiac index), Systemic Vascular resistance index (SVRI) 0h,6h on day 1
Measured: At 6 hours of admission
Documentation of Cardiac index at 24h
POC ultrasound and echocardiography documentation (Cardiac index), Systemic Vascular resistance index (SVRI) 0h,6h on day 1
Measured: At 24 hours of admission
Documentation of Cardiac index at 48h
POC ultrasound and echocardiography documentation (Cardiac index), Systemic Vascular resistance index (SVRI) 0h,6h on day 1
Measured: At 48 hours of admission
Documentation of Cardiac index at 72h
POC ultrasound and echocardiography documentation (Cardiac index), Systemic Vascular resistance index (SVRI) 0h,6h on day 1
Measured: At 72 hours of admission
Documentation of POCUS systemic vascular resistance index
POC ultrasound and echocardiography documentation for changes in (Cardiac index), Systemic Vascular resistance index (SVRI)
Measured: Time zero at admission
Documentation of POCUS systemic vascular resistance index at 6h
POC ultrasound and echocardiography documentation for changes in (Cardiac index), Systemic Vascular resistance index (SVRI)
Measured: at 6hours of admission
Documentation of POCUS systemic vascular resistance index at 24h
POC ultrasound and echocardiography documentation for changes in (Cardiac index), Systemic Vascular resistance index (SVRI)
Measured: at 24hours of admission
Documentation of POCUS systemic vascular resistance index at 48h
POC ultrasound and echocardiography documentation for changes in (Cardiac index), Systemic Vascular resistance index (SVRI)
Measured: at 48hours of admission
Documentation of POCUS systemic vascular resistance index at 72h
POC ultrasound and echocardiography documentation for changes in (Cardiac index), Systemic Vascular resistance index (SVRI)
Measured: at 72hours of admission
Documentation of IVC dynamics
POC ultrasound and echocardiography documentation for changes in (Cardiac index), Systemic Vascular resistance index (SVRI)
Measured: time zero at admission (Day 0)
Documentation of IVC dynamics
POC ultrasound and echocardiography documentation for changes in (Cardiac index), Systemic Vascular resistance index (SVRI)
Measured: At 6hours of admission (Day 1)
Documentation of IVC dynamics
POC ultrasound and echocardiography documentation for changes in echo parameters (Cardiac index), Systemic Vascular resistance index (SVRI)
Measured: at 24hours of admission
Documentation of IVC dynamics
POC ultrasound and echocardiography documentation for changes in echo parameters (Cardiac index), Systemic Vascular resistance index (SVRI)
Measured: at 48hours of admission
Documentation of IVC dynamics
POC ultrasound and echocardiography documentation for changes in echo parameters (Cardiac index), Systemic Vascular resistance index (SVRI)
Measured: at 72hours of admission
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Sep 2021
- Study start1 Feb 2020
- Primary completion1 Jul 2025
- Study completion10 Aug 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (12)Papers the sponsor has linked to this study.
- Other trials for Cirrhosis, LiverStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 350 participants (actual)
Sponsor and investigators
- Lead sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Madhumita Premkumar, Post Graduate Institute of Medical Education and Research, Chandigarh
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05059795
- Sponsor's protocol ID
- Im/2019/2917
- Status last verified
- Aug 2025
- First submitted
- 4 Jul 2020
- Last updated
- 2 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Moreau R, Hadengue A, Soupison T, Kirstetter P, Mamzer MF, Vanjak D, Vauquelin P, Assous M, Sicot C. Septic shock in patients with cirrhosis: hemodynamic and metabolic characteristics and intensive care unit outcome. Crit Care Med. 1992 Jun;20(6):746-50. doi: 10.1097/00003246-199206000-00008.
PubMed 1597026ARISE Investigators; ANZICS Clinical Trials Group; Peake SL, Delaney A, Bailey M, Bellomo R, Cameron PA, Cooper DJ, Higgins AM, Holdgate A, Howe BD, Webb SA, Williams P. Goal-directed resuscitation for patients with early septic shock. N Engl J Med. 2014 Oct 16;371(16):1496-506. doi: 10.1056/NEJMoa1404380. Epub 2014 Oct 1.
PubMed 25272316Marik PE, Baram M, Vahid B. Does central venous pressure predict fluid responsiveness? A systematic review of the literature and the tale of seven mares. Chest. 2008 Jul;134(1):172-8. doi: 10.1378/chest.07-2331.
PubMed 18628220Bentzer P, Griesdale DE, Boyd J, MacLean K, Sirounis D, Ayas NT. Will This Hemodynamically Unstable Patient Respond to a Bolus of Intravenous Fluids? JAMA. 2016 Sep 27;316(12):1298-309. doi: 10.1001/jama.2016.12310.
PubMed 27673307Velissaris D, Pierrakos C, Scolletta S, De Backer D, Vincent JL. High mixed venous oxygen saturation levels do not exclude fluid responsiveness in critically ill septic patients. Crit Care. 2011 Jul 26;15(4):R177. doi: 10.1186/cc10326.
PubMed 21791090Lee YK, Hwang SY, Shin TG, Jo IJ, Suh GY, Jeon K. Prognostic Value of Lactate and Central Venous Oxygen Saturation after Early Resuscitation in Sepsis Patients. PLoS One. 2016 Apr 7;11(4):e0153305. doi: 10.1371/journal.pone.0153305. eCollection 2016.
PubMed 27054713Lee J, de Louw E, Niemi M, Nelson R, Mark RG, Celi LA, Mukamal KJ, Danziger J. Association between fluid balance and survival in critically ill patients. J Intern Med. 2015 Apr;277(4):468-77. doi: 10.1111/joim.12274. Epub 2014 Jun 27.
PubMed 24931482Sefidbakht S, Assadsangabi R, Abbasi HR, Nabavizadeh A. Sonographic measurement of the inferior vena cava as a predictor of shock in trauma patients. Emerg Radiol. 2007 Jul;14(3):181-5. doi: 10.1007/s10140-007-0602-4. Epub 2007 Jun 1.
PubMed 17541661Premkumar M, Rangegowda D, Kajal K, Khumuckham JS. Noninvasive estimation of intravascular volume status in cirrhosis by dynamic size and collapsibility indices of the inferior vena cava using bedside echocardiography. JGH Open. 2019 Mar 12;3(4):322-328. doi: 10.1002/jgh3.12166. eCollection 2019 Aug.
PubMed 31406926Jansen TC, van Bommel J, Schoonderbeek FJ, Sleeswijk Visser SJ, van der Klooster JM, Lima AP, Willemsen SP, Bakker J; LACTATE study group. Early lactate-guided therapy in intensive care unit patients: a multicenter, open-label, randomized controlled trial. Am J Respir Crit Care Med. 2010 Sep 15;182(6):752-61. doi: 10.1164/rccm.200912-1918OC. Epub 2010 May 12.
PubMed 20463176Du W, Liu DW, Wang XT, Long Y, Chai WZ, Zhou X, Rui X. Combining central venous-to-arterial partial pressure of carbon dioxide difference and central venous oxygen saturation to guide resuscitation in septic shock. J Crit Care. 2013 Dec;28(6):1110.e1-5. doi: 10.1016/j.jcrc.2013.07.049.
PubMed 24216336Izzy M, VanWagner LB, Lin G, Altieri M, Findlay JY, Oh JK, Watt KD, Lee SS; Cirrhotic Cardiomyopathy Consortium. Redefining Cirrhotic Cardiomyopathy for the Modern Era. Hepatology. 2020 Jan;71(1):334-345. doi: 10.1002/hep.30875. Epub 2019 Oct 11.
PubMed 31342529
Study at a glance
From the registry record, last updated by the sponsor on 2 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- To Compare the Effectiveness of Various Methods of Estimating Volume Resuscitation in Patients With Cirrhosis With Sepsis Induced Hypotension
- ClinicalTrials.gov ID
- NCT05059795
- Acronym / sponsor ID
- Im/2019/2917
- Conditions
- Cirrhosis, Liver, Sepsis, Acute on Chronic Liver Failure
- Keywords
- Resuscitation in cirrhosis, Inferior vena cava dynamics, Central Venous Pressure in cirrhosis, Lactate clearance in cirrhosis, Acute-on-chronic liver failure, Sepsis in Cirrhosis, Shock in ACLF and Cirrhosis
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 350 participants (actual)
- Lead sponsor
- Post Graduate Institute of Medical Education and Research, ChandigarhUniversity, hospital or other
- Study start
- 1 Feb 2020 (actual)
- Primary completion
- 1 Jul 2025 (actual)
- Study completion
- 10 Aug 2025 (actual)
- First posted
- 28 Sep 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In critically ill patients with liver disease like cirrhosis or ACLF, fluid therapy needs to be instituted after identification of patients who will be fluid responsive and initiate appropriate inotropes early to prevent the mortality associated with fluid overload.
The parameters and methodology used for assessing fluid responsiveness have been studied earlier, but the optimum method is not established. Existing recommendations based on data regarding fluid responsiveness and choice of fluid for resuscitation from intensive care units in general cannot be applied to those with liver disease as the hemodynamic alterations that occur with liver disease, presence of hypoalbuminemia at baseline and presence of cardiac dysfunction interfere with the conventional methods of fluid status assessment, fluid responsiveness as well as the response to different types of resuscitation fluids.
Therefore the investigators attempt to compare various methods to estimate current intravascular volume status of patient which could be helpful in guiding fluid therapy.
Detailed description
Objectives:
- To compare the accuracy of central venous pressure and inferior vena cava dynamic assessment and lactate clearance for estimating adequacy of fluid resuscitation in patients with cirrhosis with sepsis induced hypotension .[Time Frame at enrolment, 6 hours, 24 hours]
- Predictors of all-cause mortality at Day 7 and day 28. [Time Frame Day 7 and Day 28]
PATIENTS AND METHODS Study Design: A Prospective observational study
Case Definition:
Cirrhosis will be defined by - "clinical features consistent with chronic liver disease (CLD) including a consistent history as well as a documented complication of CLD (i.e., ascites, varices, hepatic encephalopathy) and/or imaging results consistent with cirrhosis and/or liver histologic findings consistent with cirrhosis" ACLF will be defined as per EASL criteria with documentation of organ failures.
Systemic Inflammatory Response Syndrome (SIRS) - 2 more of following 4
- Oral temperature >38.3oC or <36oC
- Heart Rate > 90 beats/min
- Respiratory Rate >20 breaths/min or PaCO2 <32mmHg
- WBC count >12000/cumm, <4000/cumm or >10% immature band forms Sepsis is a SIRS in response to proven or suspected microbial event 'Sepsis induced hypotension' implies mean arterial pressure < 65 mmHg or a reduction of >40 mm Hg from baseline in the absence of other causes of hypotension Severe sepsis - sepsis-induced tissue hypoperfusion or organ dysfunction (any of the following thought to be due to the infection)
- Sepsis-induced hypotension
- Lactate above upper limits laboratory normal
- Urine output < 0.5 mL/kg/hr for more than 2 hrs despite adequate fluid resuscitation
- Acute lung injury with PaO2/FIO2 < 250 in the absence of pneumonia as infection source
- Acute lung injury with PaO2/FIO2 < 200 in the presence of pneumonia as infection source
- Creatinine > 2.0 mg/dL (176.8 μmol/L)
- Bilirubin > 2 mg/dL (34.2 μmol/L)
- Platelet count < 100,000 μL
- Coagulopathy (international normalized ratio > 1.5) Septic shock is "sepsis induced hypotension despite adequate fluid resuscitation along with organ dysfunction or perfusion abnormality".
Acute kidney injury (AKI) is defined as any of the following:
- Increase in SCr by ≥0.3 mg/dl (≥26.5 μmol/l) within 48 hours; or
- Increase in SCr to ≥1.5 times baseline, which is known or presumed to have occurred within the prior 7 days; or
- Urine volume <0.5 ml/kg/h for 6 hours
Definition of Adequate Intravascular volume - IVC diameter ≥ 18mm and IVCCI <40% Definition of Adequate fluid resuscitation - Achieving MAP ≥ 65mmHg with Fluid bolus
All patients eligible for the study will undergo screening as per the above criteria. The ones who satisfy the criteria will be counselled for participation in the study and written informed consent will be taken from the patient / the legal guardian in patients who are unable to do so. Patient information sheets will also be signed, briefing the patients about why the research work is necessary and also about the methodology.
Detail history and clinical examination will be done in all cases and the findings along with all investigation results will be recorded in a standard case record form. Information would be collected regarding the onset and duration of symptoms, etiology, and severity of disease, other baseline clinical features, demographic characteristics, routine biochemical and hematological investigations.
- After enrolment, baseline samples would be taken for routine investigations and samples for evaluation of sepsis - blood culture, urine culture, fluid cultures, procalcitonin will be taken.
- The patient would be assessed for 5 parameters and will be reassessed 30min and 4hours after starting fluid resuscitation.
- IVC diameter and collapsibility Index
- Serum lactate levels
- Venous-arterial pCO2 difference
- CVP where central line inserted as per treating physician's decision
- ScVO2 where central line available
- The patients in septic shock where IVC diameter <18mm or IVCCI≥40% in spontaneously breathing patients, would be regarded in fluid depleted state and will be given aggressive fluid resuscitation with 20% albumin 100 ml started within 30 min which is a standard fluid of choice in patients with cirrhosis and other fluids - Normal Saline/ balanced salt solution 30ml/kg over 3hrs. (The patients who not fulfil above criteria would be assumed in a fluid replete state and be started on maintenance fluid management along with inotrope support as per standard dosage guidelines) Norepinephrine would be 1st choice vasopressor - started at a dose of 4μg/min and titrated every 20 min to a maximum of 21.3μg/min. If MAP still <65mmHg, Vasopressor would be added starting from a 0.01U/min to 0.04U/min. Adrenaline would be added in shock refractory to both vasopressors in dose of 4-24μg/min.
- Along with fluid and inotrope support, the patient will also receive standard of care including empiric broad spectrum antibiotics, oxygen support/ventilator support if needed.
- MAP would be rechecked 30 min after starting fluid therapy. IVC diameter and IVCCI would also be checked at same time to see if change in MAP (if any) is reflected in the IVC status. Adequate fluid resuscitation would be defined by achieving a MAP ≥ 65mmHg. In patients achieving MAP≥65mmHg, fluid therapy will be continued. The patients still having MAP<65 mmHg will be started on inotrope support according to standard guidelines.
- IVC, IVCCI, Lactate, venous-arterial pCO2 difference, CVP and ScVO2 would be remeasured at 4 hrs.
- The patient would be the followed with serial examinations, calculations of SOFA score, CTP and MELD.
- Samples to test for sepsis such as procalcitonin, galactomannan, beta D Glucan and high sensitivity CRP will be done every 48-72 hours as determined by the treating clinician.
- Cultures for bacterial and fungal sepsis will be taken as per the Liver ICU protocol.
- If discharged earlier, for the purpose of 28-day mortality the patients' kin would be contacted telephonically.
- Data regarding total amount of fluids, type of fluids, urine output, dose and duration of inotropes, initiation of RRT, total days in ICU/Hospital, immediate cause of death (In case of mortality) would be noted.
Presence of Cirrhotic Cardiomyopathy as per updated 2020 CCMC criteria.
CCM is defined as systolic or diastolic dysfunction in the absence of alternative cardiac pathology in concordance with the Cirrhotic Cardiomyopathy Consortium (CCMC) criteria. 9 Systolic dysfunction was defined as an ejection fraction (EF) ≤50% or an absolute value of GLS <18%. LVDD will be defined as presence of 3 of the following 4 criteria: septal early diastolic mitral annular flow velocity (e') <7 cm/s, early diastolic transmitral flow to early diastolic mitral annular velocity (E/e') ≥15, left atrial volume index (LAVI) >34 mL/m2, tricuspid jet maximum velocity >2.8 m/s, in the absence of pulmonary hypertension and the presence of measurable early to late diastolic transmitral flow velocity (E/A) ratio (E/A >2 = grade 3 \& E/A 0.8-2 = grade 2 LVDD). Persons meeting only 2 criteria will be termed as indeterminate for LVDD grade. 19
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Cirrhosis/ACLF of any etiology | – | Drug: Albumin + electrolyte solution, Diagnostic Test: POCUS guided fluid resuscitation |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients 18-65 years age with cirrhosis of any etiology now presenting with sepsis induced hypotension
Key inclusion criteria (3 listed)
- Clinical/Imaging or Biopsy proven liver cirrhosis of any etiology
- Hypotension (MAP <65mmHg or SBP <90mmHg)
- 18-65 yrs of age
Key exclusion criteria (12 listed)
- Already received colloid or 2 litres of fluid within the first 2 hours of presentation, without echocardiographic assessment.
- Already on vasopressors/inotropes
- Severe pre-existing cardiopulmonary disease
- Acute Respiratory Distress Syndrome (ARDS)
- Active bleeding like variceal bleed 28
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Albumin + electrolyte solutionAlso: CrystalloidType of resuscitation fluid, dose and use of inotrope | Drug | Cirrhosis/ACLF of any etiology |
| POCUS guided fluid resuscitationConventional goal directed therapy | Diagnostic test | Cirrhosis/ACLF of any etiology |
Primary outcome
Achievement of Mean Arterial pressure >65 mmHg
Time frame: At the end of 4 hours since admission (time zero)
29 secondary outcomes
Requirement of vasopressors
Time frame: At the end of 4 hours of admission
Requirement of vasopressors
Time frame: At the end of 24 hours of admission
Volume of fluid infused
Time frame: At the end of 4 hours of admission
Volume of fluid infused
Time frame: At the end of 24 hours of admission
Volume of fluid infused
Time frame: At the end of 36 hours of admission
Volume of fluid infused
Time frame: At the end of 48 hours of admission
Volume of fluid infused
Time frame: At the end of 72 hours of admission
Incidence of Acute Kidney Injury
Time frame: At admission
Incidence of Acute Kidney Injury
Time frame: Day 7
Incidence of new organ dysfunction (encephalopathy, coagulation failure, respiratory failure)
Time frame: Day 7
Duration of ICU stay
Time frame: Total duration of ICU stay in days
Duration of hospital stay
Time frame: Total duration of admission as a hospital inpatient, assessed till 28 days
Mortality
Time frame: Day 7
Mortality
Time frame: Day 28
Documentation of Cardiac index
Time frame: Time zero at admission
Documentation of Cardiac index at 6h
Time frame: At 6 hours of admission
Documentation of Cardiac index at 24h
Time frame: At 24 hours of admission
Documentation of Cardiac index at 48h
Time frame: At 48 hours of admission
Documentation of Cardiac index at 72h
Time frame: At 72 hours of admission
Documentation of POCUS systemic vascular resistance index
Time frame: Time zero at admission
Documentation of POCUS systemic vascular resistance index at 6h
Time frame: at 6hours of admission
Documentation of POCUS systemic vascular resistance index at 24h
Time frame: at 24hours of admission
Documentation of POCUS systemic vascular resistance index at 48h
Time frame: at 48hours of admission
Documentation of POCUS systemic vascular resistance index at 72h
Time frame: at 72hours of admission
Documentation of IVC dynamics
Time frame: time zero at admission (Day 0)
Documentation of IVC dynamics
Time frame: At 6hours of admission (Day 1)
Documentation of IVC dynamics
Time frame: at 24hours of admission
Documentation of IVC dynamics
Time frame: at 48hours of admission
Documentation of IVC dynamics
Time frame: at 72hours of admission
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Sep 2025.
- Background: PubMed 1597026Moreau R, Hadengue A, Soupison T, Kirstetter P, Mamzer MF, Vanjak D, Vauquelin P, Assous M, Sicot C. Septic shock in patients with cirrhosis: hemodynamic and metabolic characteristics and intensive care unit outcome. Crit Care Med. 1992 Jun;20(6):746-50. doi: 10.1097/00003246-199206000-00008.
- Background: PubMed 25272316ARISE Investigators; ANZICS Clinical Trials Group; Peake SL, Delaney A, Bailey M, Bellomo R, Cameron PA, Cooper DJ, Higgins AM, Holdgate A, Howe BD, Webb SA, Williams P. Goal-directed resuscitation for patients with early septic shock. N Engl J Med. 2014 Oct 16;371(16):1496-506. doi: 10.1056/NEJMoa1404380. Epub 2014 Oct 1.
- Background: PubMed 18628220Marik PE, Baram M, Vahid B. Does central venous pressure predict fluid responsiveness? A systematic review of the literature and the tale of seven mares. Chest. 2008 Jul;134(1):172-8. doi: 10.1378/chest.07-2331.
- Background: PubMed 27673307Bentzer P, Griesdale DE, Boyd J, MacLean K, Sirounis D, Ayas NT. Will This Hemodynamically Unstable Patient Respond to a Bolus of Intravenous Fluids? JAMA. 2016 Sep 27;316(12):1298-309. doi: 10.1001/jama.2016.12310.
- Background: PubMed 21791090Velissaris D, Pierrakos C, Scolletta S, De Backer D, Vincent JL. High mixed venous oxygen saturation levels do not exclude fluid responsiveness in critically ill septic patients. Crit Care. 2011 Jul 26;15(4):R177. doi: 10.1186/cc10326.
- Background: PubMed 27054713Lee YK, Hwang SY, Shin TG, Jo IJ, Suh GY, Jeon K. Prognostic Value of Lactate and Central Venous Oxygen Saturation after Early Resuscitation in Sepsis Patients. PLoS One. 2016 Apr 7;11(4):e0153305. doi: 10.1371/journal.pone.0153305. eCollection 2016.
- Background: PubMed 24931482Lee J, de Louw E, Niemi M, Nelson R, Mark RG, Celi LA, Mukamal KJ, Danziger J. Association between fluid balance and survival in critically ill patients. J Intern Med. 2015 Apr;277(4):468-77. doi: 10.1111/joim.12274. Epub 2014 Jun 27.
- Background: PubMed 17541661Sefidbakht S, Assadsangabi R, Abbasi HR, Nabavizadeh A. Sonographic measurement of the inferior vena cava as a predictor of shock in trauma patients. Emerg Radiol. 2007 Jul;14(3):181-5. doi: 10.1007/s10140-007-0602-4. Epub 2007 Jun 1.
- Background: PubMed 31406926Premkumar M, Rangegowda D, Kajal K, Khumuckham JS. Noninvasive estimation of intravascular volume status in cirrhosis by dynamic size and collapsibility indices of the inferior vena cava using bedside echocardiography. JGH Open. 2019 Mar 12;3(4):322-328. doi: 10.1002/jgh3.12166. eCollection 2019 Aug.
- Background: PubMed 20463176Jansen TC, van Bommel J, Schoonderbeek FJ, Sleeswijk Visser SJ, van der Klooster JM, Lima AP, Willemsen SP, Bakker J; LACTATE study group. Early lactate-guided therapy in intensive care unit patients: a multicenter, open-label, randomized controlled trial. Am J Respir Crit Care Med. 2010 Sep 15;182(6):752-61. doi: 10.1164/rccm.200912-1918OC. Epub 2010 May 12.
- Background: PubMed 24216336Du W, Liu DW, Wang XT, Long Y, Chai WZ, Zhou X, Rui X. Combining central venous-to-arterial partial pressure of carbon dioxide difference and central venous oxygen saturation to guide resuscitation in septic shock. J Crit Care. 2013 Dec;28(6):1110.e1-5. doi: 10.1016/j.jcrc.2013.07.049.
- Background: PubMed 31342529Izzy M, VanWagner LB, Lin G, Altieri M, Findlay JY, Oh JK, Watt KD, Lee SS; Cirrhotic Cardiomyopathy Consortium. Redefining Cirrhotic Cardiomyopathy for the Modern Era. Hepatology. 2020 Jan;71(1):334-345. doi: 10.1002/hep.30875. Epub 2019 Oct 11.
- Individual participant dataSharing planned: No
Related trials for Cirrhosis, Liver
RecruitingObservational study
Effectiveness and Clinical Outcomes of Long-term Bulevirtide Monotherapy in Patients With HDV-related Compensated Cirrhosis
Hepatitis D
Recruiting
Optimal Treatment Strategy for Spontaneous Bacterial Peritonitis
Spontaneous Bacterial Peritonitis, Paracentesis
RecruitingObservational study
The Value of Spleen Thickness and Spleen Diameter for Gastroesophageal Varices Diagnosis in Compensated Cirrhosis
Liver Cirrhosis, Gastroesophageal Varices
Recruiting
CirrhosisRx CDS System
Cirrhosis, Decision Support Systems, Clinical
RecruitingPhase 3
Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cirrhosis, Liver and Sepsis, run by Post Graduate Institute of Medical Education and Research, Chandigarh at 2 sites in India.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in India. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Achievement of Mean Arterial pressure >65 mmHg (time frame: At the end of 4 hours since admission (time zero)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05059795, which also lists 12 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Sep 2025.